3月10日 - ** 生物技术公司Aligos TherapeuticsALGS.O股价下跌17.3%至10.70美元，创三个月新低
** (link) 季度净亏损为每股 13.08 美元，去年同期为每股亏损 5.50 美元。
** 报告显示，2024 年的现金等价物和投资为 5690 万美元，而 2023 年为 1.357 亿美元，这将为 2026 年下半年的计划运营提供充足资金
** 公司表示正在继续评估各种方案，以资助其肝病药物的持续开发，包括潜在的对外授权
** 截至上次收盘，ALGS在过去12个月中下跌了44.3%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.